Characterization of N-diethylnitrosamine-initiated and Ferric Nitrilotriacetate-promoted Renal Cell Carcinoma Experimental Model and Effect of a Tamarind Seed Extract Against Acute Nephrotoxicity and Carcinogenesis
Overview
Authors
Affiliations
Renal cell carcinoma (RCC), the commonest malignancy in adult kidney, lacks of early signs, resulting often in metastasis at first diagnosis. N-Diethylnitrosamine (DEN)-initiated and ferric nitrilotriacetate (FeNTA)-promoted RCC may be a useful experimental model, but it is not well characterized. In this study, histological alterations and oxidative stress markers were analyzed at different times throughout RCC development, histological subtype was re-evaluated in the light of current classification, and a tamarind seed extract (TSE) effect was examined. Male Wistar rats experimental groups were control, TSE, DEN, DEN+FeNTA, and TSE+DEN+FeNTA. TSE was given 2 weeks before DEN administration (200 mg/kg) and throughout the experiment. Fourteen days after DEN treatment, two FeNTA doses (9 mg Fe/kg) for acute nephrotoxicity study, and increasing FeNTA doses (3-9 mg Fe/kg) twice a week for 16 weeks for carcinogenesis protocol, were administered. In acute study, necrosis and renal failure were observed and TSE ameliorated them. Throughout carcinogenesis protocol, preneoplastic lesions were observed since 1 month of FeNTA treatment, which were more evident at 2 months, when also renal cysts and RCC were already detected. RCC tumors were obtained without changes in renal function, and clear cell histological subtype was identified in all cases. 4-Hydroxy-2-nonenal and 3-nitro-L: -tyrosine levels increased progressively throughout protocol. TSE decreased both oxidative stress markers and, although there was no statistical difference, it delayed RCC progress and decreased its incidence (21 %). This study brings an insight of the time course events in this carcinogenesis model, identifies clear cell subtype and establishes TSE renoprotective effects.
Anti-ischemic effect of L. seed extract against myocardial hypoxic injury.
Surinkaew S, Mongkolpathumrat P, Nissapatorn V, Kumphune S F1000Res. 2024; 11:1235.
PMID: 38680230 PMC: 11046188. DOI: 10.12688/f1000research.126051.1.
Shimizu T, Miyake M, Iida K, Onishi S, Fujii T, Iemura Y Oncol Lett. 2024; 27(5):225.
PMID: 38586200 PMC: 10996032. DOI: 10.3892/ol.2024.14358.
Giselvania A, Juniantito V, Wibowo H, Siregar T, Gondhowiardjo S Cancer Manag Res. 2024; 16:245-257.
PMID: 38560662 PMC: 10979671. DOI: 10.2147/CMAR.S439787.
Greene C, Attwood K, Sharma N, Balderman B, Deng R, Muhitch J Front Oncol. 2022; 12:923043.
PMID: 35992801 PMC: 9389085. DOI: 10.3389/fonc.2022.923043.
Pariente-Perez T, Aguilar-Alonso F, Solano J, Vargas-Olvera C, Curiel-Muniz P, Mendoza-Rodriguez C Oncol Lett. 2020; 19(4):3153-3164.
PMID: 32256811 PMC: 7074249. DOI: 10.3892/ol.2020.11436.